LIGOCYTE LICENSES KEY PATENT FROM CENTER FOR BLOOD RESEARCH.LigoCyte Pharmaceuticals, Inc., Bozeman, Mont., has exclusively licensed inflammation assay technology from the Center for Blood Research, an affiliate of Harvard Medical School Harvard Medical School (HMS) is one of the graduate schools of Harvard University. It is a prestigious American medical school located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts. . Formerly a non-exclusive licensee, the company expanded its rights to the technology to enhance its franchise as a contract research provider of immunology screening services to the biotechnology and pharmaceutical industries. The patent (US No. 5,460,945) entitled "Device and Method of Analysis of Blood Components and Identifying Inhibitors and Promoters of the Inflammatory Response" was issued to Drs. Timothy Springer and Michael Lawrence at the Center for Blood Research. The patent covers in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. models of the rolling and arrest of leukocytes along the endothelial endothelial /en·do·the·li·al/ (-the´le-al) pertaining to or made up of endothelium. Endothelial A layer of cells that lines the inside of certain body cavities, for example, blood vessels. cell wall, which are important steps in the migration of leukocytes out of the blood stream and into tissue as part of the inflammatory response. "Leukocyte leukocyte (l  `kəsīt'): see blood. leukocyte or white blood cell or white corpuscle recruitment assays are a key cornerstone of our ProteoFlow(R) screening franchise," said Dr. Robert Bargatze, LigoCyte's chief scientific officer, "and this patent broadly covers a wide array of assays for evaluating inhibitors of a number of different therapeutic targets. The Center's license to LigoCyte is further validation of our position as the industry leader in the characterization of anti-inflammatory compounds." LigoCyte, established in 1998, is headquartered in Bozeman, Montana. In addition to its ProteoFlow(R) screening capabilities, the company has immunomodulatory drug immunomodulatory drug Clinical pharmacology A therapeutic agent that suppresses the immune system, inhibiting lymphocyte functions, especially T and NK cells; IDs are used to treat IBD–ulcerative colitis, Crohn's disease Examples Azathioprine, mercaptopurine discovery and development activities in support of its own pipeline of therapeutic candidates. The Center for Blood Research, an independent, non-profit biomedical research institute in Boston, Mass., is considered a world leader in research on the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . Founded in 1953, CBR (1) (Computer-Based Reference) Reference materials accessible by computer in order to help people do their jobs quicker. For example, this database on disk! (2) (Constant Bit Rate) A uniform transmission rate. now pursues six areas of concentration: adhesion molecules, autoimmunity, genetics of the immune system, immune defense against viruses and tumors, immunodeficiency, and microscopy and imaging. For more information, call 406/585-2733 or visit http://www.ligocyte.com or http://www.cbr.med.harvard.edu. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion